Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bruker Cellular Analysis, Inc.CELL · Entity 109250 | Director | October 02, 2023 | October 03, 2023 |
| Catalent, Inc.CTLT · Entity 16279 | Director · Executive Chair | August 24, 2022 | August 27, 2022 |
| QuidelOrtho CorpQDEL · Entity 4986 | Director | June 25, 2026 | June 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bruker Cellular Analysis, Inc.
Report date October 02, 2023 · Filed October 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2023-10-02 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-10-02 · Disposition to issuer · Disposed 71,225 · Balance 41,240 F1: On October 2, 2023, pursuant to the Agreement and Plan of Merger dated as of August 17, 2023 (the "Merger Agreement"), by and among Bruker Corporation ("Bruker"), Bird Mergersub Corporation ("Merger Sub") and Phenomex Inc. (the "Company"), Merger Sub merged with and into the Company, with the Company surviving the Merger as a wholly owned subsidiary of Bruker (the "Merger"), and each restricted stock unit ("RSU") held by the Reporting Person was cancelled and converted into the right to receive $1.00 per share in cash (the "Merger Consideration"). F2: Pursuant to the Merger, the Reporting Person disposed of each RSU held by him in exchange for the Merger Consideration. Row 2 · 2023-10-02 · Disposition to issuer · Disposed 41,240 · Balance 0 F3: Pursuant to the Merger Agreement, each outstanding share of Common Stock, par value $0.00005 per share ("Common Stock") held by the Reporting Person was cancelled and converted into the right to receive the Merger Consideration. F4: Pursuant to the Merger, the Reporting Person disposed of all shares of Common Stock beneficially owned by him in exchange for the Merger Consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: On October 2, 2023, pursuant to the Agreement and Plan of Merger dated as of August 17, 2023 (the "Merger Agreement"), by and among Bruker Corporation ("Bruker"), Bird Mergersub Corporation ("Merger Sub") and Phenomex Inc. (the "Company"), Merger Sub merged with and into the Company, with the Company surviving the Merger as a wholly owned subsidiary of Bruker (the "Merger"), and each restricted stock unit ("RSU") held by the Reporting Person was cancelled and converted into the right to receive $1.00 per share in cash (the "Merger Consideration").
F2: Pursuant to the Merger, the Reporting Person disposed of each RSU held by him in exchange for the Merger Consideration.
F3: Pursuant to the Merger Agreement, each outstanding share of Common Stock, par value $0.00005 per share ("Common Stock") held by the Reporting Person was cancelled and converted into the right to receive the Merger Consideration.
F4: Pursuant to the Merger, the Reporting Person disposed of all shares of Common Stock beneficially owned by him in exchange for the Merger Consideration.
Catalent, Inc.
Report date August 24, 2022 · Filed August 27, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 229,888 |
Last balance in matching sequence
After 2022-08-25 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2022-08-24 · Grant · Acquired 99,275 · Balance 268,822 F1: Received upon the achievement of the fiscal 2020-22 performance-based vesting criteria set forth in certain incentive compensation held by the reporting person under the Issuer's long-term incentive plan. F2: Includes restricted stock units. Row 2 · 2022-08-25 · Sale · Disposed 38,934 · Balance 229,888 F3: Shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of performance share units received pursuant to the Issuer's long-term incentive plan. No shares were withheld by or surrendered to the Issuer. F2: Includes restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Received upon the achievement of the fiscal 2020-22 performance-based vesting criteria set forth in certain incentive compensation held by the reporting person under the Issuer's long-term incentive plan.
F2: Includes restricted stock units.
F3: Shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of performance share units received pursuant to the Issuer's long-term incentive plan. No shares were withheld by or surrendered to the Issuer.
QuidelOrtho Corp
Report date June 25, 2026 · Filed June 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock Units (Equity Grant)SEC Table II · derivative / convertible security | Direct | 15,532 |
Reported balance
After 2026-06-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-25 · Grant · Acquired 15,532 · Balance 15,532 F1: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2: The restricted stock units will vest on June 25, 2027. |
| Restricted Stock Units (Converted)SEC Table II · derivative / convertible security | Direct | 5,547 |
Reported balance
After 2026-06-25 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-25 · Grant · Acquired 5,547 · Balance 5,547 F1: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F3: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. F4: 1,386 shares vested on June 25, 2026, 1,387 shares will vest on September 25, 2026, 1,387 shares will vest on December 25, 2026, and 1,387 shares will vest on March 25, 2027. |
| Restricted Stock Units (Premium)SEC Table II · derivative / convertible security | Direct | 1,109 |
Reported balance
After 2026-06-25 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-25 · Grant · Acquired 1,109 · Balance 1,109 F1: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2: The restricted stock units will vest on June 25, 2027. F3: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock.
F2: The restricted stock units will vest on June 25, 2027.
F3: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule.
F4: 1,386 shares vested on June 25, 2026, 1,387 shares will vest on September 25, 2026, 1,387 shares will vest on December 25, 2026, and 1,387 shares will vest on March 25, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 25, 2026 Filed Jun 29, 2026 22:00 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantRestricted Stock Units (Premium) · Derivative | 1,109 | $0.00 | $0.00 |
DisclosureSEC source: 0001482197-26-000003 · wk-form4_1782770418.xml · derivative · entry 3 Chiminski John R · CIK 0001482197 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,109 Underlying: Common Stock · 1,109 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2 · derivative.exercise_date: The restricted stock units will vest on June 25, 2027. F3 · derivative.exercise_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. F2 · derivative.expiration_date: The restricted stock units will vest on June 25, 2027. F3 · derivative.expiration_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. Read SEC document |
| June 25, 2026 Filed Jun 29, 2026 22:00 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantRestricted Stock Units (Converted) · Derivative | 5,547 | $0.00 | $0.00 |
DisclosureSEC source: 0001482197-26-000003 · wk-form4_1782770418.xml · derivative · entry 2 Chiminski John R · CIK 0001482197 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,547 Underlying: Common Stock · 5,547 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F3 · derivative.exercise_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. F4 · derivative.exercise_date: 1,386 shares vested on June 25, 2026, 1,387 shares will vest on September 25, 2026, 1,387 shares will vest on December 25, 2026, and 1,387 shares will vest on March 25, 2027. F3 · derivative.expiration_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. F4 · derivative.expiration_date: 1,386 shares vested on June 25, 2026, 1,387 shares will vest on September 25, 2026, 1,387 shares will vest on December 25, 2026, and 1,387 shares will vest on March 25, 2027. Read SEC document |
| June 25, 2026 Filed Jun 29, 2026 22:00 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantRestricted Stock Units (Equity Grant) · Derivative | 15,532 | $0.00 | $0.00 |
DisclosureSEC source: 0001482197-26-000003 · wk-form4_1782770418.xml · derivative · entry 1 Chiminski John R · CIK 0001482197 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,532 Underlying: Common Stock · 15,532 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2 · derivative.exercise_date: The restricted stock units will vest on June 25, 2027. F2 · derivative.expiration_date: The restricted stock units will vest on June 25, 2027. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 20:09 UTC | QuidelOrtho Corp QDEL · Entity 4986 | Exercise / conversionRestricted Stock Units (Equity Grant) · Derivative | 6,829 | $0.00 | $0.00 |
DisclosureSEC source: 0001482197-26-000002 · wk-form4_1780430962.xml · derivative · entry 2 Chiminski John R · CIK 0001482197 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,829 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F3 · derivative.exercise_date: The restricted stock units vested on May 29, 2026. F3 · derivative.expiration_date: The restricted stock units vested on May 29, 2026. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 20:09 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantCommon Stock | 6,829 | $0.00 | $0.00 |
DisclosureSEC source: 0001482197-26-000002 · wk-form4_1780430962.xml · nonDerivative · entry 1 Chiminski John R · CIK 0001482197 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,352 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 20:22 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantRestricted Stock Units (Premium ) · Derivative | 487 | $0.00 | $0.00 |
DisclosureSEC source: 0001906324-25-000126 · wk-form4_1748895750.xml · derivative · entry 3 Chiminski John R · CIK 0001482197 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 487 Underlying: Common Stock · 487 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2 · derivative.exercise_date: The restricted stock units will vest on May 29, 2026. F3 · derivative.exercise_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. F2 · derivative.expiration_date: The restricted stock units will vest on May 29, 2026. F3 · derivative.expiration_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 20:22 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantRestricted Stock Units (Converted) · Derivative | 2,439 | $0.00 | $0.00 |
DisclosureSEC source: 0001906324-25-000126 · wk-form4_1748895750.xml · derivative · entry 2 Chiminski John R · CIK 0001482197 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,439 Underlying: Common Stock · 2,439 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F3 · derivative.exercise_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. F4 · derivative.exercise_date: 609 shares vested on May 29, 2025, 610 shares will vest on August 29, 2025, 610 shares will vest on November 29, 2025 and 610 shares will vest on February 28, 2026. F3 · derivative.expiration_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. F4 · derivative.expiration_date: 609 shares vested on May 29, 2025, 610 shares will vest on August 29, 2025, 610 shares will vest on November 29, 2025 and 610 shares will vest on February 28, 2026. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 20:22 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantRestricted Stock Units (Equity Grant) · Derivative | 6,829 | $0.00 | $0.00 |
DisclosureSEC source: 0001906324-25-000126 · wk-form4_1748895750.xml · derivative · entry 1 Chiminski John R · CIK 0001482197 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,829 Underlying: Common Stock · 6,829 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2 · derivative.exercise_date: The restricted stock units will vest on May 29, 2026. F2 · derivative.expiration_date: The restricted stock units will vest on May 29, 2026. Read SEC document |
| May 22, 2025 Filed May 27, 2025 20:16 UTC | QuidelOrtho Corp QDEL · Entity 4986 | Exercise / conversionRestricted Stock Units (Equity Grant) · Derivative | 2,523 | $0.00 | $0.00 |
DisclosureSEC source: 0001906324-25-000093 · wk-form4_1748376971.xml · derivative · entry 2 Chiminski John R · CIK 0001482197 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,523 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F3 · derivative.exercise_date: The restricted stock units vested on May 22, 2025. F3 · derivative.expiration_date: The restricted stock units vested on May 22, 2025. Read SEC document |
| May 22, 2025 Filed May 27, 2025 20:16 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantCommon Stock | 2,523 | $0.00 | $0.00 |
DisclosureSEC source: 0001906324-25-000093 · wk-form4_1748376971.xml · nonDerivative · entry 1 Chiminski John R · CIK 0001482197 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,523 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 3. Read SEC document |
| October 02, 2023 Filed Oct 3, 2023 15:41 UTC | Bruker Cellular Analysis, Inc. CELL · Entity 109250 | Disposition to issuerCommon Stock | 41,240 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-019743 · doc4.xml · nonDerivative · entry 2 Chiminski John R · CIK 0001482197 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F3 · kind: Pursuant to the Merger Agreement, each outstanding share of Common Stock, par value $0.00005 per share ("Common Stock") held by the Reporting Person was cancelled and converted into the right to receive the Merger Consideration. F3 · price: Pursuant to the Merger Agreement, each outstanding share of Common Stock, par value $0.00005 per share ("Common Stock") held by the Reporting Person was cancelled and converted into the right to receive the Merger Consideration. F4 · price: Pursuant to the Merger, the Reporting Person disposed of all shares of Common Stock beneficially owned by him in exchange for the Merger Consideration. Read SEC document |
| October 02, 2023 Filed Oct 3, 2023 15:41 UTC | Bruker Cellular Analysis, Inc. CELL · Entity 109250 | Disposition to issuerCommon Stock | 71,225 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-019743 · doc4.xml · nonDerivative · entry 1 Chiminski John R · CIK 0001482197 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,240 F1 · kind: On October 2, 2023, pursuant to the Agreement and Plan of Merger dated as of August 17, 2023 (the "Merger Agreement"), by and among Bruker Corporation ("Bruker"), Bird Mergersub Corporation ("Merger Sub") and Phenomex Inc. (the "Company"), Merger Sub merged with and into the Company, with the Company surviving the Merger as a wholly owned subsidiary of Bruker (the "Merger"), and each restricted stock unit ("RSU") held by the Reporting Person was cancelled and converted into the right to receive $1.00 per share in cash (the "Merger Consideration"). F1 · price: On October 2, 2023, pursuant to the Agreement and Plan of Merger dated as of August 17, 2023 (the "Merger Agreement"), by and among Bruker Corporation ("Bruker"), Bird Mergersub Corporation ("Merger Sub") and Phenomex Inc. (the "Company"), Merger Sub merged with and into the Company, with the Company surviving the Merger as a wholly owned subsidiary of Bruker (the "Merger"), and each restricted stock unit ("RSU") held by the Reporting Person was cancelled and converted into the right to receive $1.00 per share in cash (the "Merger Consideration"). F2 · price: Pursuant to the Merger, the Reporting Person disposed of each RSU held by him in exchange for the Merger Consideration. Read SEC document |
| May 25, 2023 Filed Jun 1, 2023 16:25 UTC | Bruker Cellular Analysis, Inc. CELL · Entity 109250 | GrantCommon Stock | 70,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-067058 · tm2317396d5_4.xml · nonDerivative · entry 1 Chiminski John R · CIK 0001482197 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,465 F1 · shares: Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of the first anniversary of the date of grant or the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date. F2 · balance_after: Includes 71,634 RSUs. Read SEC document |
| August 25, 2022 Filed Aug 27, 2022 00:16 UTC | Catalent, Inc. CTLT · Entity 16279 | SaleCommon Stock | 38,934 | $103.04 | $4,011,759.36 |
DisclosureSEC source: 0001596783-22-000112 · wf-form4_166155936728147.xml · nonDerivative · entry 2 Chiminski John R · CIK 0001482197 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,888 F3 · shares: Shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of performance share units received pursuant to the Issuer's long-term incentive plan. No shares were withheld by or surrendered to the Issuer. F2 · balance_after: Includes restricted stock units. Read SEC document |
| August 24, 2022 Filed Aug 27, 2022 00:16 UTC | Catalent, Inc. CTLT · Entity 16279 | GrantCommon Stock | 99,275 | $0.00 | $0.00 |
DisclosureSEC source: 0001596783-22-000112 · wf-form4_166155936728147.xml · nonDerivative · entry 1 Chiminski John R · CIK 0001482197 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,822 F1 · shares: Received upon the achievement of the fiscal 2020-22 performance-based vesting criteria set forth in certain incentive compensation held by the reporting person under the Issuer's long-term incentive plan. F2 · balance_after: Includes restricted stock units. Read SEC document |
| July 26, 2022 Filed Jul 28, 2022 23:41 UTC | Catalent, Inc. CTLT · Entity 16279 | GrantCommon Stock | 37,165 | $0.00 | $0.00 |
DisclosureSEC source: 0001596783-22-000064 · wf-form4_165905168301707.xml · nonDerivative · entry 2 Chiminski John R · CIK 0001482197 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,547 F3 · shares: Restricted stock units (RSUs) received by the reporting person pursuant to the Issuer's annual grant to executive officers and other personnel under its long-term incentive plan. Each RSU represents the right to receive one share of the Issuer's common stock as of the date of vesting, which will occur three (3) years from the date of award. F2 · balance_after: Includes restricted stock units. Read SEC document |
| July 26, 2022 Filed Jul 28, 2022 23:41 UTC | Catalent, Inc. CTLT · Entity 16279 | SaleCommon Stock | 9,691 | $106.90 | $1,035,967.90 |
DisclosureSEC source: 0001596783-22-000064 · wf-form4_165905168301707.xml · nonDerivative · entry 1 Chiminski John R · CIK 0001482197 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,382 F1 · shares: Shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units received pursuant to the Issuer's long-term incentive plan. No shares were withheld by or surrendered to the Issuer. F2 · balance_after: Includes restricted stock units. Read SEC document |
| May 26, 2022 Filed Aug 1, 2022 18:50 UTC | Bruker Cellular Analysis, Inc. BLI · Entity 109250 | GrantStock Option (Right to Buy) · Derivative | 32,258 | $0.00 Strike: $4.60 | $0.00 |
DisclosureSEC source: 0001567619-22-014735 · doc1.xml · derivative · entry 2 Chiminski John R · CIK 0001482197 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,258 Underlying: Common Stock · 32,258 shares Expires 2032-05-25 F3 · derivative.exercise_date: The stock options will fully vest on May 26, 2023. Read SEC document |
| May 26, 2022 Filed Aug 1, 2022 18:50 UTC | Bruker Cellular Analysis, Inc. BLI · Entity 109250 | GrantCommon Stock | 19,565 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-014735 · doc1.xml · nonDerivative · entry 1 Chiminski John R · CIK 0001482197 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,465 F1 · shares: Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on May 26, 2023. F2 · balance_after: Includes 22,832 RSUs Read SEC document |
| March 11, 2022 Filed Mar 15, 2022 20:14 UTC | Bruker Cellular Analysis, Inc. BLI · Entity 109250 | PurchaseCommon Stock | 18,000 | $5.18 | $93,272.40 |
DisclosureSEC source: 0001567619-22-007009 · doc1.xml · nonDerivative · entry 1 Chiminski John R · CIK 0001482197 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,900 F1 · price: The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $5.08 to $5.28. The reporting person undertakes to provide Berkeley Lights, Inc (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 22:51 UTC | Catalent, Inc. CTLT · Entity 16279 | Exercise / conversionOptions to purchase Common Stock · Derivative | 34,635 | $0.00 Strike: $43.88 | $0.00 |
DisclosureSEC source: 0001596783-21-000140 · wf-form4_163347425797354.xml · derivative · entry 13 Chiminski John R · CIK 0001482197 · Director · Chair & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,638 Underlying: Common Stock · 34,635 shares Expires 2028-07-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in order to implement a plan of financial diversification. F13 · derivative.exercise_date: The options vest and become exercisable in four equal annual installments beginning on July 23, 2019. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 22:51 UTC | Catalent, Inc. CTLT · Entity 16279 | Exercise / conversionOptions to purchase Common Stock · Derivative | 15,264 | $0.00 Strike: $34.91 | $0.00 |
DisclosureSEC source: 0001596783-21-000140 · wf-form4_163347425797354.xml · derivative · entry 12 Chiminski John R · CIK 0001482197 · Director · Chair & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,264 shares Expires 2027-08-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in order to implement a plan of financial diversification. F12 · derivative.exercise_date: The options vest and become exercisable in four equal annual installments beginning on August 23, 2018. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 22:51 UTC | Catalent, Inc. CTLT · Entity 16279 | Exercise / conversionOptions to purchase Common Stock · Derivative | 25,939 | $0.00 Strike: $36.02 | $0.00 |
DisclosureSEC source: 0001596783-21-000140 · wf-form4_163347425797354.xml · derivative · entry 11 Chiminski John R · CIK 0001482197 · Director · Chair & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,939 shares Expires 2027-07-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in order to implement a plan of financial diversification. F11 · derivative.exercise_date: The options vest and become exercisable in four equal annual installments beginning on July 24, 2018. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 22:51 UTC | Catalent, Inc. CTLT · Entity 16279 | SaleCommon Stock | 4,888 | $132.86 | $649,419.68 |
DisclosureSEC source: 0001596783-21-000140 · wf-form4_163347425797354.xml · nonDerivative · entry 10 Chiminski John R · CIK 0001482197 · Director · Chair & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,073 F3 · kind: Shares sold pursuant to the Rule 10b5-1 trading plan noted in footnote 1. F10 · price: Volume-weighted average price. These shares were sold in multiple transactions at prices ranging from $132.74 to $133.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 22:51 UTC | Catalent, Inc. CTLT · Entity 16279 | SaleCommon Stock | 64,031 | $132.18 | $8,463,617.58 |
DisclosureSEC source: 0001596783-21-000140 · wf-form4_163347425797354.xml · nonDerivative · entry 9 Chiminski John R · CIK 0001482197 · Director · Chair & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,961 F3 · kind: Shares sold pursuant to the Rule 10b5-1 trading plan noted in footnote 1. F9 · price: Volume-weighted average price. These shares were sold in multiple transactions at prices ranging from $131.74 to $132.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 22:51 UTC | Catalent, Inc. CTLT · Entity 16279 | SaleCommon Stock | 26,662 | $131.21 | $3,498,321.02 |
DisclosureSEC source: 0001596783-21-000140 · wf-form4_163347425797354.xml · nonDerivative · entry 8 Chiminski John R · CIK 0001482197 · Director · Chair & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,992 F3 · kind: Shares sold pursuant to the Rule 10b5-1 trading plan noted in footnote 1. F8 · price: Volume-weighted average price. These shares were sold in multiple transactions at prices ranging from $130.72 to $131.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 22:51 UTC | Catalent, Inc. CTLT · Entity 16279 | SaleCommon Stock | 21,245 | $130.39 | $2,770,135.55 |
DisclosureSEC source: 0001596783-21-000140 · wf-form4_163347425797354.xml · nonDerivative · entry 7 Chiminski John R · CIK 0001482197 · Director · Chair & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,654 F3 · kind: Shares sold pursuant to the Rule 10b5-1 trading plan noted in footnote 1. F7 · price: Volume-weighted average price. These shares were sold in multiple transactions at prices ranging from $129.72 to $130.71, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 22:51 UTC | Catalent, Inc. CTLT · Entity 16279 | SaleCommon Stock | 12,700 | $129.22 | $1,641,094.00 |
DisclosureSEC source: 0001596783-21-000140 · wf-form4_163347425797354.xml · nonDerivative · entry 6 Chiminski John R · CIK 0001482197 · Director · Chair & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,899 F3 · kind: Shares sold pursuant to the Rule 10b5-1 trading plan noted in footnote 1. F6 · price: Volume-weighted average price. These shares were sold in multiple transactions at prices ranging from $128.72 to $129.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 22:51 UTC | Catalent, Inc. CTLT · Entity 16279 | SaleCommon Stock | 18,510 | $128.10 | $2,371,131.00 |
DisclosureSEC source: 0001596783-21-000140 · wf-form4_163347425797354.xml · nonDerivative · entry 5 Chiminski John R · CIK 0001482197 · Director · Chair & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,599 F3 · kind: Shares sold pursuant to the Rule 10b5-1 trading plan noted in footnote 1. F5 · price: Volume-weighted average price. These shares were sold in multiple transactions at prices ranging from $127.71 to $128.69, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 22:51 UTC | Catalent, Inc. CTLT · Entity 16279 | SaleCommon Stock | 4,601 | $127.34 | $585,891.34 |
DisclosureSEC source: 0001596783-21-000140 · wf-form4_163347425797354.xml · nonDerivative · entry 4 Chiminski John R · CIK 0001482197 · Director · Chair & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 290,109 F3 · kind: Shares sold pursuant to the Rule 10b5-1 trading plan noted in footnote 1. F4 · price: Volume-weighted average price. These shares were sold in multiple transactions at prices ranging from $126.68 to $127.67, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 22:51 UTC | Catalent, Inc. CTLT · Entity 16279 | Exercise / conversionCommon Stock | 34,635 | $43.88 | $1,519,783.80 |
DisclosureSEC source: 0001596783-21-000140 · wf-form4_163347425797354.xml · nonDerivative · entry 3 Chiminski John R · CIK 0001482197 · Director · Chair & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 294,710 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in order to implement a plan of financial diversification. F2 · balance_after: Includes restricted stock units. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 22:51 UTC | Catalent, Inc. CTLT · Entity 16279 | Exercise / conversionCommon Stock | 15,264 | $34.91 | $532,866.24 |
DisclosureSEC source: 0001596783-21-000140 · wf-form4_163347425797354.xml · nonDerivative · entry 2 Chiminski John R · CIK 0001482197 · Director · Chair & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,075 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in order to implement a plan of financial diversification. F2 · balance_after: Includes restricted stock units. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 22:51 UTC | Catalent, Inc. CTLT · Entity 16279 | Exercise / conversionCommon Stock | 25,939 | $36.02 | $934,322.78 |
DisclosureSEC source: 0001596783-21-000140 · wf-form4_163347425797354.xml · nonDerivative · entry 1 Chiminski John R · CIK 0001482197 · Director · Chair & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,811 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in order to implement a plan of financial diversification. F2 · balance_after: Includes restricted stock units. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 20:44 UTC | Catalent, Inc. CTLT · Entity 16279 | GiftCommon Stock | 11,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001596783-21-000136 · wf-form4_163070188408348.xml · nonDerivative · entry 1 Chiminski John R · CIK 0001482197 · Director · Chair & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,872 F1 · kind: This transaction was a charitable donation effective September 1, 2021 in which no value was received in return. F2 · balance_after: Includes restricted stock units. Read SEC document |
| August 27, 2021 Filed Aug 31, 2021 01:39 UTC | Catalent, Inc. CTLT · Entity 16279 | SaleCommon Stock | 40,888 | $131.12 | $5,361,234.56 |
DisclosureSEC source: 0001596783-21-000123 · wf-form4_163037392904985.xml · nonDerivative · entry 3 Chiminski John R · CIK 0001482197 · Director · Chair & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,872 F3 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in order to cover tax withholding obligations in connection with the vesting of performance share units received pursuant to the Issuer's long-term incentive plan. No shares were withheld by or surrendered to the Issuer. F5 · price: Volume-weighted average price. These shares were sold in multiple transactions at prices ranging from $130.81 to $131.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units. Read SEC document |
| August 27, 2021 Filed Aug 31, 2021 01:39 UTC | Catalent, Inc. CTLT · Entity 16279 | SaleCommon Stock | 3,600 | $130.41 | $469,476.00 |
DisclosureSEC source: 0001596783-21-000123 · wf-form4_163037392904985.xml · nonDerivative · entry 2 Chiminski John R · CIK 0001482197 · Director · Chair & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,760 F3 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in order to cover tax withholding obligations in connection with the vesting of performance share units received pursuant to the Issuer's long-term incentive plan. No shares were withheld by or surrendered to the Issuer. F4 · price: Volume-weighted average price. These shares were sold in multiple transactions at prices ranging from $129.81 to $130.79, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units. Read SEC document |
| August 26, 2021 Filed Aug 31, 2021 01:39 UTC | Catalent, Inc. CTLT · Entity 16279 | GrantCommon Stock | 105,418 | $0.00 | $0.00 |
DisclosureSEC source: 0001596783-21-000123 · wf-form4_163037392904985.xml · nonDerivative · entry 1 Chiminski John R · CIK 0001482197 · Director · Chair & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,360 F1 · kind: Received upon the achievement of the fiscal 2019-21 performance-based vesting criteria set forth in certain incentive compensation held by the reporting person under the Issuer's long-term incentive plan. F2 · balance_after: Includes restricted stock units. Read SEC document |
| July 26, 2021 Filed Jul 28, 2021 20:25 UTC | Catalent, Inc. CTLT · Entity 16279 | GrantOptions to purchase Common Stock · Derivative | 85,165 | $0.00 Strike: $113.00 | $0.00 |
DisclosureSEC source: 0001596783-21-000090 · wf-form4_162750392958280.xml · derivative · entry 3 Chiminski John R · CIK 0001482197 · Director · Chair & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,165 Underlying: Common Stock · 85,165 shares Expires 2031-07-26 F5 · shares: Received by the reporting person pursuant to the Issuer's annual grant to executive officers and other personnel under its long-term incentive plan. F6 · derivative.exercise_date: The options vest and become exercisable in four equal annual installments beginning on July 26, 2022. Read SEC document |
| July 26, 2021 Filed Jul 28, 2021 20:25 UTC | Catalent, Inc. CTLT · Entity 16279 | GrantCommon Stock | 16,461 | $0.00 | $0.00 |
DisclosureSEC source: 0001596783-21-000090 · wf-form4_162750392958280.xml · nonDerivative · entry 2 Chiminski John R · CIK 0001482197 · Director · Chair & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,942 F4 · shares: Restricted stock units (RSUs) received by the reporting person pursuant to the Issuer's annual grant to executive officers and other personnel under its long-term incentive plan. Each RSU represents the right to receive one share of the Issuer's common stock as of the date of vesting, which will occur three (3) years from the date of award. F3 · balance_after: Includes restricted stock units. Read SEC document |
| July 26, 2021 Filed Jul 28, 2021 20:25 UTC | Catalent, Inc. CTLT · Entity 16279 | SaleCommon Stock | 11,137 | $113.05 | $1,259,037.85 |
DisclosureSEC source: 0001596783-21-000090 · wf-form4_162750392958280.xml · nonDerivative · entry 1 Chiminski John R · CIK 0001482197 · Director · Chair & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,481 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in order to cover tax withholding obligations in connection with the vesting of restricted stock received pursuant to the Issuer's long-term incentive plan. No shares were withheld by or surrendered to the Issuer. F2 · price: Volume-weighted average price. These shares were sold in multiple transactions at prices ranging from $112.77 to $113.38, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes restricted stock units. Read SEC document |
| May 14, 2021 Filed May 18, 2021 21:44 UTC | Bruker Cellular Analysis, Inc. BLI · Entity 109250 | GrantStock Option (Right to Buy) · Derivative | 4,900 | $0.00 Strike: $37.13 | $0.00 |
DisclosureSEC source: 0001567619-21-010677 · doc1.xml · derivative · entry 2 Chiminski John R · CIK 0001482197 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,900 Underlying: Common Stock · 4,900 shares Expires 2031-05-13 F2 · derivative.exercise_date: The stock option will vest in 36 equal monthly installments until fully vested on May 14, 2024. Read SEC document |
| May 14, 2021 Filed May 18, 2021 21:44 UTC | Bruker Cellular Analysis, Inc. BLI · Entity 109250 | GrantCommon Stock | 4,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-010677 · doc1.xml · nonDerivative · entry 1 Chiminski John R · CIK 0001482197 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,900 F1 · shares: Represents an award of restricted stock units which will vest with respect to one-third of the shares on May 14, 2022, and will vest with respect to the remainder of the shares in equal quarterly installments thereafter until fully vested on May 14, 2024. The restricted stock units will be settled in shares of the Issuer's common stock upon vesting. Read SEC document |
| March 19, 2021 Filed Mar 22, 2021 18:19 UTC | Catalent, Inc. CTLT · Entity 16279 | Exercise / conversionOptions to purchase Common Stock · Derivative | 32,374 | $0.00 Strike: $54.94 | $0.00 |
DisclosureSEC source: 0001596783-21-000045 · wf-form4_161643718240512.xml · derivative · entry 14 Chiminski John R · CIK 0001482197 · Director · Chair & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,123 Underlying: Common Stock · 32,374 shares Expires 2029-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in order to implement a plan of financial diversification. F11 · derivative.exercise_date: The options vest and become exercisable in four equal annual installments beginning on July 22, 2020. Read SEC document |
| March 19, 2021 Filed Mar 22, 2021 18:19 UTC | Catalent, Inc. CTLT · Entity 16279 | Exercise / conversionOptions to purchase Common Stock · Derivative | 69,270 | $0.00 Strike: $43.88 | $0.00 |
DisclosureSEC source: 0001596783-21-000045 · wf-form4_161643718240512.xml · derivative · entry 13 Chiminski John R · CIK 0001482197 · Director · Chair & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,273 Underlying: Common Stock · 69,270 shares Expires 2028-07-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in order to implement a plan of financial diversification. F10 · derivative.exercise_date: The options vest and become exercisable in four equal annual installments beginning on July 23, 2019. Read SEC document |
| March 19, 2021 Filed Mar 22, 2021 18:19 UTC | Catalent, Inc. CTLT · Entity 16279 | Exercise / conversionOptions to purchase Common Stock · Derivative | 45,792 | $0.00 Strike: $34.91 | $0.00 |
DisclosureSEC source: 0001596783-21-000045 · wf-form4_161643718240512.xml · derivative · entry 12 Chiminski John R · CIK 0001482197 · Director · Chair & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,264 Underlying: Common Stock · 45,792 shares Expires 2027-08-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in order to implement a plan of financial diversification. F9 · derivative.exercise_date: The options vest and become exercisable in four equal annual installments beginning on August 23, 2018. Read SEC document |
| March 19, 2021 Filed Mar 22, 2021 18:19 UTC | Catalent, Inc. CTLT · Entity 16279 | Exercise / conversionOptions to purchase Common Stock · Derivative | 35,588 | $0.00 Strike: $36.02 | $0.00 |
DisclosureSEC source: 0001596783-21-000045 · wf-form4_161643718240512.xml · derivative · entry 11 Chiminski John R · CIK 0001482197 · Director · Chair & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,939 Underlying: Common Stock · 35,588 shares Expires 2027-07-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in order to implement a plan of financial diversification. F8 · derivative.exercise_date: The options vest and become exercisable in four equal annual installments beginning on July 24, 2018. Read SEC document |
| March 19, 2021 Filed Mar 22, 2021 18:19 UTC | Catalent, Inc. CTLT · Entity 16279 | SaleCommon Stock | 800 | $107.07 | $85,656.00 |
DisclosureSEC source: 0001596783-21-000045 · wf-form4_161643718240512.xml · nonDerivative · entry 9 Chiminski John R · CIK 0001482197 · Director · Chair & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,618 F3 · kind: Shares sold pursuant to the Rule 10b5-1 trading plan noted in footnote 1. F7 · price: Volume-weighted average price. These shares were sold in multiple transactions at prices ranging from $107.00 to $107.11, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units. Read SEC document |
| March 19, 2021 Filed Mar 22, 2021 18:19 UTC | Catalent, Inc. CTLT · Entity 16279 | SaleCommon Stock | 111,641 | $106.24 | $11,860,739.84 |
DisclosureSEC source: 0001596783-21-000045 · wf-form4_161643718240512.xml · nonDerivative · entry 8 Chiminski John R · CIK 0001482197 · Director · Chair & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,418 F3 · kind: Shares sold pursuant to the Rule 10b5-1 trading plan noted in footnote 1. F6 · price: Volume-weighted average price. These shares were sold in multiple transactions at prices ranging from $106.00 to $106.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units. Read SEC document |
| March 19, 2021 Filed Mar 22, 2021 18:19 UTC | Catalent, Inc. CTLT · Entity 16279 | SaleCommon Stock | 70,583 | $105.64 | $7,456,388.12 |
DisclosureSEC source: 0001596783-21-000045 · wf-form4_161643718240512.xml · nonDerivative · entry 7 Chiminski John R · CIK 0001482197 · Director · Chair & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 276,059 F3 · kind: Shares sold pursuant to the Rule 10b5-1 trading plan noted in footnote 1. F5 · price: Volume-weighted average price. These shares were sold in multiple transactions at prices ranging from $105.00 to $105.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units. Read SEC document |
| March 19, 2021 Filed Mar 22, 2021 18:19 UTC | Catalent, Inc. CTLT · Entity 16279 | Exercise / conversionCommon Stock | 32,374 | $54.94 | $1,778,627.56 |
DisclosureSEC source: 0001596783-21-000045 · wf-form4_161643718240512.xml · nonDerivative · entry 6 Chiminski John R · CIK 0001482197 · Director · Chair & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 346,642 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in order to implement a plan of financial diversification. F2 · balance_after: Includes restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.